Live updates


Cancer breakthrough drugs may not be 'cost effective'

A combination of cancer drugs that can shrink skin cancer tumours in more than half of patients may not be cost-effective for the NHS to supply patients.

A British-led trial has found immune-boosting drugs - ipilimumab and nivolumab - stopped advanced melonoma for nearly a year in 58% of cases.

But the high success rate comes with a high price tag, as ITV News' Health Editor Rachel Younger reports:

Cancer treatment success 'will depend on patient suitability'

How much patients benefit from the new immuno-therapy treatment announced today in the fight against cancer will depend on which drugs suit them best, according to a leading expert.

Speaking to ITV News, Dr Alan Worsley of Cancer Research UK said that patients might respond best to one type of drug or a combination of therapies.


Load more updates